Kymera Therapeutics (KYMR) Change in Acquisitions & Divestments (2020 - 2026)

Kymera Therapeutics (KYMR) has 7 years of Change in Acquisitions & Divestments data on file, last reported at $133.9 million in Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments rose 0.85% year-over-year to $133.9 million in Q1 2026; TTM through Mar 2026 was $489.1 million, a 9.96% decrease from a year earlier, with the FY2025 full-year figure at $488.0 million, down 4.31% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $133.9 million, up from $103.9 million in the prior quarter.
• Over the last five years, Change in Acquisitions & Divestments for KYMR reached as high as $147.9 million in Q4 2024 and fell as low as $76.1 million in Q4 2023.
• Historically, Change in Acquisitions & Divestments has averaged $115.6 million across 5 years, with a median of $117.7 million in 2022.
• Across the five-year window, Change in Acquisitions & Divestments plunged 32.6% in 2023 and surged 94.43% in 2024, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $97.9 million in 2022, then declined by 22.32% to $76.1 million in 2023, then jumped by 94.43% to $147.9 million in 2024, then declined by 29.78% to $103.9 million in 2025, then rose by 28.87% to $133.9 million in 2026.
• Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were $133.9 million in Q1 2026, $103.9 million in Q4 2025, and $132.4 million in Q3 2025.